Commissioning Policy for Cough Assist Requests

Similar documents
Neuromuscular diseases (NMDs) include both hereditary and acquired diseases of the peripheral neuromuscular system. They are diseases of the

The objectives of this presentation are to

Alternative title: Confessions of a Mucus Enthusiast. Mechanical Insufflation Exsufflation for airway secretion clearance and lung expansion therapy

CoughAssist E70. More than just a comfortable cough. Flexible therapy that brings more comfort to your patients airway clearance

[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below

The difference is clear. CoughAssist clears airways with the force of a natural cough

Motor Neurone Disease NICE to manage Management of ineffective cough. Alex Long Specialist NIV/Respiratory physiotherapist June 2016

RESPIRATORY COMPLICATIONS AFTER SCI

Operation Manual for clinical use of SIARE Pulsar

MedStar Health considers Cough Assist Devices medically necessary for the following indications:

LUNG VOLUME RECRUITMENT IN NEUROMUSCULAR DISEASE

Preventing Respiratory Complications of Muscular Dystrophy

Cardiorespiratory Physiotherapy Tutoring Services 2017

Respiratory Management- Your Questions Answered! Michelle Chatwin, PhD Consultant Physiotherapist

Problem-solving Respiratory Issues in Children With Neuromuscular Disease. December 13, 2018 Eliezer Be eri, M.D.

MND Study Day. Martin Latham CNS Leeds Sleep Service

Mechanical Ventilation of the Patient with Neuromuscular Disease

Terapias no farmacológicas de aclaramiento de la vía aérea y soporte respiratorio muscular en

Benefit of Forced Expiratory Technique for Weak Cough in a Patient with Bulbar Onset Amyotrophic Lateral Sclerosis

Physiotherapy on the Intensive Care Unit. Information for patients, their family and carers

A Comparison of Cough Assistance Techniques in Patients with Respiratory Muscle Weakness

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

Policies and Procedures

Is mechanical insufflation exsufflation (M-IE) useful in children with neuromuscular disease?

Mechanical Insufflation-Exsufflation Versus Conventional Chest Physiotherapy in Children With Cerebral Palsy

Airway Clearance Applications in the Elderly and in Patients With Neurologic or Neuromuscular Compromise

KENNEDY DISEASE PULMONARY CONSIDERATIONS: SCIENCE & MANAGEMENT STRATEGIES

Respiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician

Clinical Policy Title: Mechanical airway clearance devices

Key points. k Ineffective cough is a major cause of

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Cough Assist. Information for patients, families and carers Therapy Services

Clearway Cough Assistor for Home Use

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

H: Respiratory Care. Saskatchewan Association of Licensed Practical Nurses, Competency Profile for LPNs, 3rd Ed. 79

Pediatric Patients. Neuromuscular Disease. Teera Kijmassuwan, MD Phetcharat Netmuy, B.N.S., MA Oranee Sanmaneechai, MD : Preceptor

The great majority of neuromuscular disease morbidity. Prevention of Pulmonary Morbidity for Patients With Neuromuscular Disease*

NIV - BI-LEVEL POSITIVE AIRWAY PRESSURE (BIPAP)

Endobronchial valve insertion to reduce lung volume in emphysema

Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600

F: Respiratory Care. College of Licensed Practical Nurses of Alberta, Competency Profile for LPNs, 3rd Ed. 59

(Non)-invasive ventilation: transition from PICU to home. Christian Dohna-Schwake

Artificial External Glottic Device for Passive Lung Insufflation

The Effects of Breathing Exercise with Intermittent Positive Pressure Ventilator on Pulmonary Function in Patients with Cervical Spinal Cord Injury

AFCH NEUROMUSCULAR DISORDERS (NMD) PROTOCOL

Airway clearance in neuromuscular weakness

Clinical Policy Title: Mechanical airway clearance devices

Competency Title: Continuous Positive Airway Pressure

Cough assist T70 for the Tracheostomy Child

BiLevel Pressure Device

High Frequency Chest Wall Oscillating Devices (HFCWO) (Airway Clearance Systems)

SCOTTISH MUSCLE NETWORK DUCHENNE MUSCULAR DYSTROPHY TRANSITION SOME USEFUL THINGS TO KNOW ABOUT HEALTH AROUND ADOLESCENCE

IPPB via the Servo I Guidelines for use in UCH Critical Care.

Pulmonary Rehabilitation in Acute Spinal Cord Injury. Jatuporn Jatutawanit Physical therapist, Physical therapy unit, Prince of songkla university

TTC Catalog - Respiratory Care (RES)

Section: Universal Benefit Programs. Respiratory Equipment Program

Bench Assessment of a New Insufflation-Exsufflation Device

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Understanding Breathing Muscle Weakness

What is the next best step?

Ron Hosp, MS-HSA, RRT Regional Respiratory Specialist. This program has been approved for 1 hour of continuing education credit.

Hyperinflation Therapy and the Tools to Accomplish It!! Bill Barnes, RN, RRT Good Shepherd Rehabilitation Network

Respiratory implications of motor neurone disease

I. Subject: Continuous Positive Airway Pressure CPAP by Continuous Flow Device

Pneumothorax in chronically ventilated neuromuscular and chest wall restricted patients: A case series

Sample Case Study. The patient was a 77-year-old female who arrived to the emergency room on

County of Santa Clara Emergency Medical Services System

Extract from EFFECTIVE CLINICAL COMMISSIONING POLICIES

MASTER SYLLABUS

Ratified by: Care and Clinical Policies Date: 17 th February 2016

Item Number: 6 NHS VALE OF YORK CLINICAL COMMISSIONING GROUP GOVERNING BODY MEETING. Meeting Date: 7 November Report Author: Report Sponsor:

POLICY. Number: Title: APPLICATION OF NON INVASIVE VENTILATION FOR ACUTE RESPIRATORY FAILURE. Authorization

PomPom SHOOTER. Activity Background: Common Obstructive Lung Disorders:

Tracheostomy. Hope Building Neurosurgery

King s Research Portal

Olesoxime for amyotrophic lateral sclerosis first line

1 Chapter 13 Respiratory Emergencies 2 Respiratory Distress Patients often complain about. Shortness of breath Symptom of many different Cause can be

Do Not Cite. For Public Comment Period DRAFT MEASURE #3: Evaluation of Pulmonary Status Ordered MUSCULAR DYSTROPHY

COMMISSION ON ACCREDITATION FOR RESPIRATORY CARE TMC DETAILED CONTENT OUTLINE COMPARISON

Respiratory care and ventilation

Spinal Muscular Atrophy: Case Study. Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting

Invest to Save: Jackie Baillie MSP (Chair, Cross Party Group on Muscular Dystrophy) Eileen McCallum

Pulmo-Park Pom-Pom Shooter: Measuring the Effect of Restricted Breathing on Peak Expiratory Flow (PEF) Student Information Page Activity 5D

CYSTIC FIBROSIS INPATIENT PROTOCOL PURPOSE POLICY STATEMENTS SITE APPLICABILITY PRACTICE LEVEL/COMPETENCIES DEFINITIONS EQUIPMENT

Dr. CK NG Department of Medicine Queen Elizabeth Hospital Kowloon Central Cluster

PRIMARY CARE CO-COMMISSIONING COMMITTEE. 9 June 2015

Airway Clearance Devices

GOVERNING BODY MEETING in Public 22 February 2017 Agenda Item 3.4

Limits of Effective Cough-Augmentation Techniques in Patients With Neuromuscular Disease

National Cancer Action Team. Rehabilitation Care Pathway Poor Mobility and Loss of Function

Adapting to the Worsening of the LTMV Patient

CLINICAL CONSIDERATIONS FOR THE BUNNELL LIFE PULSE HIGH-FREQUENCY JET VENTILATOR

Raxone (idebenone) and pulmonary care in Duchenne Muscular Dystrophy (DMD)

BREATHLESSNESS MANAGEMENT

Small Volume Nebulizer Treatment (Hand-Held)

VitaBreath. Helping your COPD patients remain active

PULMONARY FUNCTION. VOLUMES AND CAPACITIES

Policy Specific Section: October 1, 2010 January 21, 2013

Respiratory Muscle Strength and Cough Capacity in Patients with Duchenne Muscular Dystrophy

Transcription:

Commissioning Policy for Cough Assist Requests 1

DOCUMENT CONTROL Reference Number (lead in specific policy area to provide once policy ratified) Version Draft Version 0.3 071015 Status Sponsor(s)/Author(s) Wendy Godwin Lead Commissioner Planned Care/Head of Elective Care Pathways Amendments Date By whom Approved by IFR panel 07/09/1 5 IFR Panel Members Approved Planned Care Programme Board 14/09/1 5 Programme Members Board Intended Recipients: Head of Patient Safety and Quality Improvement IFR team Group/Persons Consulted: Sally Roberts Robert Saunders and Dr Uma Viswanathan Planned Care Programme Board Monitoring Arrangements and Indicators: IFR database Training/Resource Implications: None CCG Value: Approving Body: Improving Outcomes Committee Ensure equity in access for all patients Date Approved: 18 th February 2016 Date of Issue 1 st April 2016 Review Date 1 st April 2018 Contact for Review Lead Commissioner Planned Care/Head of Elective Care Pathways 2

Policy Location: Intranet CCG Website Summary Evidence Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) New evidence includes a systematic review, several RCTs, crossover trials, case series and retrospective cohort study, and overall the studies suggest that MI-E to assist cough is at least as effective as manual assisted cough. 2 RCTs found MI-E to be superior to other methods. N.B. Much of the evidence is for neuromuscular disease, but the clinical challenge is much the same in Spinal Cord Injury Patients who have an ineffective/weak cough due to neuromuscular disease and cervical spinal cord injury. Specifically patients with conditions such as muscular dystrophy, spinal muscular atrophy, motor neurone disease and spinal cord injury Use of cough-assist machine is vital to enable expectoration of phlegm or mucus from throat or lungs, thus preventing A&E admission and emergency intubation. Respiratory function should be assessed in people with more complex care needs and consideration should be made of support from speech and language therapists and physiotherapist who as part of an MDT assessment can recommend appropriate interventions such as cough assist devices. Abstract The MDT may include palliative care and respiratory nurses to support people, for patients who require intensive interventions and cough assistance, and a rehabilitation consultation to advise on the best course of action when a significant worsening of symptoms occurs This commissioning policy describes the use of the cough assist machine to augment/assist an ineffective cough (determined by a reduced cough peak flow) in patients with neuro-muscular disease and spinal cord injury Contents Number Section Page No. 1.0 Introduction and Evidence 4 3

2.0 Implications 4 3.0 Prior Approval 5 4.0 Appendices 6 Commissioning Policy for Cough Assist Requests 1.0 Introduction and Evidence The mechanical insufflator/exsufflator (MI-E) assists the clearance of bronchopulmonary secretions in those patients with an ineffective cough by the use of both positive and negative pressure. Cough Assist is a non-invasive therapy that safely and consistently removes secretions in patients with an ineffective ability to cough (peak cough flow <270 l/m). The Cough Assist device clears secretions by gradually applying a positive pressure to the airway, then rapidly shifting to negative pressure. The rapid shift in pressure produces a high expiratory flow, simulating a natural cough. 1.1 Benefits of Cough Assist Removes secretions from the lungs Reduces the occurrence of respiratory infections Safe, non-invasive alternative to suctioning Easy for patients and caregivers to operate 1.2 Cough Assist Flexibility Can be used with a face mask, mouthpiece or with an adapter to a patient's endotracheal or tracheostomy tube Approved for home use in adults and children Available in automatic and manual models 1.3 Indications for Use 1.3.1 Typical Cough Assist patients include those with the following conditions: Amyotrophic lateral sclerosis Spinal muscular atrophy Muscular dystrophy Myasthenia gravis Spinal cord injuries Reduced Peak Cough Flow (PCF) of 160l/pm or 270 l/pm or < 270 l/pm and have clinical symptoms or a weak cough and therefor require intervention necessary to clear bronchial secretions or infection PCF can be measured by coughing into a peak flow meter attached to a mask MI-E Guidelines 2013 3 1.4 Contraindications Any patient with a history of bullous emphysema Susceptibility to pneumothorax or pnuemo-mediastinum Recent barotrauma, should be carefully considered before use The above contraindications should be carefully considered before use. 4

2.0 Implications Legal and/or Risk CQC Patient Safety Patient Engagement Financial Sustainability The risks of not providing this equipment outweighs the financial risks of making it available N/A The Cough Assist Device piece can be required and may even be essential for the safe and timely discharge of spinal injury patient s from an acute spinal bed into their own homes in the community. BCNA representatives as Lay members are involved in the development of the policy as members of the Neurological Task and Finish Group Reduction in spend on low priority treatments. The estimated cost for the Cough Assist equipment is 4,500 per patient with an additional 500 per year, on-going costs. Based on the current levels of demand the CCG would expect to have one patient every two years requiring the equipment. NHS England has commissioning responsibility for the acute treatment of spinal cord injuries. Their policy does however make it clear that responsibility passes back to CCGs once the patient is discharged from Acute care. The Cough Assist Device has been specifically mentioned as an item that CCGs may be required to provide for patients with suppressed cough reflex to support their discharge. NHS England policy also indicates that CCGs will be charged the cost of excess bed days resulting from delayed discharge if this equipment is not available. Protection of finance for essential (high priority) services Workforce/Training The service provider will also arrange training on an ad-hoc basis. 3.0 Prior Approval This commissioning proforma covers the use Mechanical Insufflation-Exsufflation (MI-E) therapy for patients with neuromuscular disorders and cervical spinal cord injury patients 3.1 Clinical Indications for Funding 3.1.1. An established diagnosis as paralytic/restrictive disorder including but not exclusively: spinal cord injuries (SCI) neuromuscular diseases such as ALS Guillain-Barré Syndrome myasthenia gravis muscular dystrophy multiple sclerosis post polio kypho-scoliosis syringomyelia 5

3.2.2. Patient is unable to cough or clear secretions effectively with a PCF (Peak Cough Flow) less than 160 L/min VC (vital capacity) below 1.1L in general respiratory muscle weakness, or voluntary Reduced Peak Cough Flow (PCF) of 270 l/pm or < 270 l/pm and have clinical symptoms or a weak cough and therefor require intervention necessary to clear bronchial secretions or infection Requests for MI-E or 'cough assist therapy' for patients who do not meet the above criteria are considered low priority and will not be routinely funded. 3.2 Absolute Contra-Indications Presence of haemoptysis, untreated or recent pneumothorax, bullous emphysema, nausea and emesis, severe COPD, severe asthma and recent lobectomy Increased intra cranial pressure (ICP) including ventricular drains Impaired consciousness / inability to communicate in instances where the patient does NOT have an artificial airway 3.2.1 Relative Contraindications therapy immediately following meals tachypnea history of COPD and pneumothorax large pleural effusion cervical spinal injury unclear hemodynamic instability impaired consciousness / inability to communicate where the patient has an artificial airway Supplemental oxygen should not be bled into the MI-E circuit. Oxygen passing through the fan system during the exsufflation phase results in a potential fire hazard Appendix 1 References 1. Motor Neurone Disease a Problem Solving Approach for General Practitioners and Allied Health Professionals 2011 http://www.mndscotland.org.uk/wpcontent/uploads/2011/08/a-problem-solving-approach-2012.pdf 2. National Institute for Health and Care Excellence Multiple Sclerosis Stakeholder Comments Draft Guideline June 2014 http://www.mssociety.org.uk/sites/default/files/documents/campaigns%20resources/ms- Society-response-to-draft-NICE-clinical-guideline-MS.pdf 3. NHS Evidence https://www.evidence.nhs.uk/search?q=cough+assist+machines 4. Nottingham University Hospital NHS Trust Cough Assist Guideline August 2013 6

5. Muscular Dystrophy UK 2015 #Right To Breath Campaign http://www.musculardystrophyuk.org/news/campaign-success-as-nhs-bosses-incornwall-agree-to-fund-cough-assist-machines/ Appendix 2 Evidence Base 1. Bach JR et al. Mechanical insufflation-exsufflation. Comparison of peak expiratory flows with manually assisted and unassisted coughing techniques.chest. 1993 Nov;104(5):1553-62 2. Berlly M et al. Respiratory Management During the First Five Days After Spinal Cord Injury. J Spinal Cord Med. 2007; 30(4): 309 318 3. Chatwin M et al. Cough Augmentation with Mechanical Insufflation/Exsufflation in Patients with Neuromuscular Weakness. Eur Respir J: March 2003;21(3):502-508 4. LeBlanc C Asthma / COPD Educator Professional Practice Leader, Respiratory Therapy The Ottawa Hospital Rehabilitation Centre McKim Douglas A MD, FRCPC, FCCP, D,ABSM Medical Director, Respiratory Rehabilitation Services Associate Professor, Department of Medicine University of Ottawa 5. Reid WD et al. Physiotherapy Secretion Removal Techniques in People With Spinal Cord Injury: A Systematic Review. J Spinal Cord Med. 2010;33(4):353 370 6. Respiratory Therapy Policy And Procedure Mechanical Insufflation-Exsufflation for Paralytic/Restrictive Disorders. 7. Sancho J et al. Mechanical in/exsufflation vs tracheal suctioning via tracheostomy tubes for patients with amyotrophic lateral sclerosis: a pilot study. Am J Phys Med Rehabil 2003;82(10)750-753 8. Tzeng AC & Bach JR. Prevention of Pulmonary Morbidity or Patients with Neuromuscular Disease. Chest 2000;118: 1390-1396 9. Winck JC et al. Effects of mechanical insufflation-exsufflation on respiratory parameters for patients with chronic airway secretion encumbrance. Chest. 2004;126:774-780 7